According to the Zhitong Finance App, Zuoli Pharmaceutical (300181.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”), agreeing to carry out clinical trial research on the new functional treatment of the company's marketed product, Linglian Granule. After review, the clinical trial application for Linglianhua granules accepted on June 1, 2026 met the relevant requirements for drug registration. On the basis of further improving the clinical trial plan, it was agreed that this product would carry out clinical trials for perimenopausal syndrome with anxiety without cardiac and renal certification.

According to the Zhitong Finance App, Zuoli Pharmaceutical (300181.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”), agreeing to carry out clinical trial research on the new functional treatment of the company's marketed product, Linglian Granule. After review, the clinical trial application for Linglianhua granules accepted on June 1, 2026 met the relevant requirements for drug registration. On the basis of further improving the clinical trial plan, it was agreed that this product would carry out clinical trials for perimenopausal syndrome with anxiety without cardiac and renal certification.